Literature DB >> 11156871

Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome.

S Hoshida1, J Kato, M Nishino, Y Egami, T Takeda, M Kawabata, J Tanouchi, Y Yamada, T Kamada.   

Abstract

BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors are effective in the secondary prevention of ischemic heart disease, but they do not reduce the rate of restenosis. Vascular ACE activity in the culprit coronary lesions of these patients, however, has never been quantified. METHODS AND
RESULTS: We measured the ACE activity of vascular tissue obtained by directional coronary atherectomy in patients with acute coronary syndrome (n=17) and in patients with stable ischemic heart disease (n=36), with and without restenosis. The ACE activity of the culprit coronary lesions was significantly increased in patients with acute coronary syndrome (0.87+/-0.12 nmol. min(-1). mg protein(-1); P:<0.01) but not in patients with ischemic heart disease with restenosis (n=11, 0.19+/-0.05 nmol. min(-1). mg protein(-1)) when compared with those patients with ischemic heart disease without restenosis (n=25, 0.20+/-0.05 nmol. min(-1). mg protein(-1)). There was no difference between the ACE activity of the coronary tissue of the in-stent (n=5) and stent-unrelated (n=6) restenosis patients (0.24+/-0.10 versus 0.15+/-0.04 nmol. min(-1). mg protein(-1)). Serum ACE activity did not differ significantly among the patients.
CONCLUSIONS: The present study demonstrates increased ACE activity in culprit lesions in acute coronary syndrome, indicating that enhanced ACE activity is related to the causative mechanism of active coronary lesions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11156871     DOI: 10.1161/01.cir.103.5.630

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

1.  LDL cholesterol angiotensin II interactions in atherosclerosis.

Authors:  F C Luft
Journal:  J Mol Med (Berl)       Date:  2001-05       Impact factor: 4.599

2.  Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus.

Authors:  D C Sharman; A D Morris; A D Struthers
Journal:  Diabetologia       Date:  2007-08-04       Impact factor: 10.122

3.  Increased expression and co-localization of ACE, angiotensin II AT(1) receptors and inducible nitric oxide synthase in atherosclerotic human coronary arteries.

Authors:  Mitsuru Ohishi; Gregory J Dusting; Paul A Fennessy; Frederick Ao Mendelsohn; Xiao C Li; Jia L Zhuo
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-04-30

Review 4.  Angiotensin antagonism in coronary artery disease: results after coronary revascularisation.

Authors:  Flavio Ribichini; Valeria Ferrero; Andrea Rognoni; Giovanni Vacca; Corrado Vassanelli
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Synergism between paraoxonase Arg 192 and the angiotensin converting enzyme D allele is associated with severity of coronary artery disease.

Authors:  Asad Vaisi-Raygani; Zohreh Rahimi; Haidar Tavilani; Hadiss Vaisi-Raygani; A Kiani; M Aminian; E Shakiba; Y Shakiba; Tayebeh Pourmotabbed
Journal:  Mol Biol Rep       Date:  2011-06-17       Impact factor: 2.316

Review 6.  Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?

Authors:  Christian Werner; Janine Pöss; Michael Böhm
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

7.  Alterations in biomarkers of endothelial function following on-pump coronary artery revascularization.

Authors:  Ioannis Panagiotopoulos; George Palatianos; Argyris Michalopoulos; Antonios Chatzigeorgiou; Sotirios Prapas; Elli F Kamper
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

Review 8.  RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.

Authors:  Christian Werner; Magnus Baumhäkel; Koon K Teo; Roland Schmieder; Johannes Mann; Thomas Unger; Salim Yusuf; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2008-05-03       Impact factor: 5.460

Review 9.  Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story.

Authors:  Roberto Ferrari; Kim Fox
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  Effect of Angiotensin-converting Enzyme Inhibitor on Cardiac Fibrosis and Oxidative Stress Status in Lipopolysaccharide-induced Inflammation Model in Rats.

Authors:  Azam Abareshi; Fatemeh Norouzi; Fereshteh Asgharzadeh; Farimah Beheshti; Mahmoud Hosseini; Mehdi Farzadnia; Majid Khazaei
Journal:  Int J Prev Med       Date:  2017-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.